We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-5.74%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$625M
AUM Growth
+$350M
Cap. Flow
+$339M
Cap. Flow %
54.24%
Top 10 Hldgs %
74.87%
Holding
79
New
22
Increased
18
Reduced
8
Closed
20

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$13.9M
2
AZN icon
AstraZeneca
AZN
+$9.59M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$7.78M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$5.91M
5
ESTA icon
Establishment Labs
ESTA
+$5.67M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$9.29M
2
BBIO icon
BridgeBio Pharma
BBIO
+$8.24M
3
CYTK icon
Cytokinetics
CYTK
+$6.63M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.53M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$4.09M

Sector Composition

Rank Sector Weight
1 Healthcare 34.14%
2 Financials 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.16M 0.5%
+30,000
New +$2.92M
OBIO icon
27
Orchestra BioMed
OBIO
$222M
$2.97M 0.48%
300,000
– –
MSAC
28
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$2.93M 0.47%
300,000
– –
TVTX icon
29
Travere Therapeutics
TVTX
$5.19B
$2.58M 0.41%
100,000
+50,000
+100% +$1.33M
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$2.45M 0.39%
70,000
-155,000
-69% -$4.53M
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.49B
$2.45M 0.39%
80,000
-70,500
-47% -$2.11M
NAUT icon
32
Nautilus Biotechnolgy
NAUT
$219M
$2.43M 0.39%
559,019
-490,702
-47% -$2.01M
GBT
33
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.42M 0.39%
+70,000
New +$2.09M
RLAY icon
34
CALL
Relay Therapeutics
RLAY
$4.23B
$2.25M 0.36%
+75,000
New +$1.82M
LNTH icon
35
PUT
Lantheus
LNTH
$6.93B
$2.21M 0.35%
+40,000
New +$1.5M
AUPH icon
36
CALL
Aurinia Pharmaceuticals
AUPH
$1.97B
$2.17M 0.35%
+175,000
New +$2.7M
ACRS icon
37
Aclaris Therapeutics
ACRS
$786M
$1.72M 0.28%
100,000
-300,000
-75% -$4.09M
BEAM icon
38
CALL
Beam Therapeutics
BEAM
$2.74B
$1.72M 0.28%
+30,000
New +$1.97M
CNTX icon
39
Context Therapeutics
CNTX
$56M
$1.69M 0.27%
+777,610
New +$1.64M
BGMS
40
Bio Green Med Solution Inc
BGMS
$4.97M
$1.22M 0.2%
111
– –
LIAN
41
DELISTED
LianBio American Depositary Shares
LIAN
$1.21M 0.19%
325,000
+252,594
+349% +$1.04M
SNCE
42
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.18M 0.19%
11,069
+3,569
+48% +$559K
KRTX
43
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$951K 0.15%
+7,500
New +$844K
VRDN icon
44
Viridian Therapeutics
VRDN
$2.09B
$925K 0.15%
+50,000
New +$961K
ATHX
45
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$858K 0.14%
+56,656
New +$1.19M
RCOR
46
DELISTED
Renovacor, Inc.
RCOR
$846K 0.14%
199,490
+74,490
+60% +$445K
CRIS icon
47
Curis
CRIS
$8.97M
$833K 0.13%
875
-750
-46% -$957K
CELU icon
48
PUT
Celularity
CELU
$22.6M
$697K 0.11%
+8,000
New +$479K
CNTA
49
DELISTED
Centessa Pharmaceuticals
CNTA
$586K 0.09%
65,282
-353,862
-84% -$3.23M
CALA
50
DELISTED
Calithera Biosciences, Inc
CALA
$404K 0.06%
+50,000
New +$511K
1
2
3

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Affinity Asset Advisors held 79 positions worth $625M, up 127% from $275M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Affinity Asset Advisors deployed $339M of net new capital in Q1 2022, opening 22 new positions and adding to 18 existing holdings. Its largest new stake was Ascendis Pharma A/S: 120,000 shares worth $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 75% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $4.53M trimmed.

  • Affinity Asset Advisors's largest Q1 2022 buy was Ascendis Pharma A/S: 120,000 shares worth $14.1M.
  • Affinity Asset Advisors added most to Inari Medical, Inc. Common Stock in Q1 2022, an estimated $7.78M increase.
  • Affinity Asset Advisors's biggest Q1 2022 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $4.53M.
  • Affinity Asset Advisors fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $9.29M.
  • Affinity Asset Advisors's ten largest holdings make up 75% of its $625M portfolio in Q1 2022.
  • Affinity Asset Advisors opened 22 new positions and closed 20 in Q1 2022.
  • Affinity Asset Advisors's portfolio value rose 127% quarter-over-quarter to $625M.

Based on Affinity Asset Advisors's 13F filing for Q1 2022, filed 13 May 2022.